Sustained virologic response ( SVR ) 24 weeks after end of treatment ( SVR24 ) , including patients treated with 12 or 24 additional weeks of peginterferon + ribavirin , was 67 % for TRIPLE ( VX-222 400 mg twice daily ) and 79 and 90 % for QUAD ( VX-222 100 and 400 mg twice daily , respectively ) .